Bristol-Myers Squibb, USA
Pharmaceutical Company Partners
Since 2004, IPM has negotiated five non-exclusive and one exclusive royalty-free license agreements, and one exclusive worldwide rights agreement from pharmaceutical companies to develop, manufacture and distribute nine antiretroviral (ARV) drugs as microbicides in developing countries.
These licenses ensure that any new product will be available at little or no cost to women in developing countries where incidence of HIV is especially high.
|Compound||License||Mechanism of action||IPM development stage|
|Dapivirine||Janssen Sciences Ireland Unlimited Company (previously Tibotec)||NNRTI: Reverse transcription|
|DS003(BMS793)||BMS||gp120: Cell attachment|
|Darunavir||Janssen Sciences Ireland Unlimited Company||Protease inhibitor: Protein synthesis and assembly|
|Maraviroc||ViiV Healthcare||CCR5: Cell Attachment|
|Tenofovir||Gilead||NRTI: Reverse transcription|
|DS001 (L167), DS004 (L872), DS005 (L882)||Merck||CCR5: Cell Attachment|
|DS007 (L-644 peptide)||Merck||gp41: Cell fusion|
* Compound is in different stages of development by other organizations
IPM continually seeks opportunities to work with pharmaceutical companies and other public and private sector research-based organizations and institutions to collaborate on developing promising microbicide and other HIV prevention products.